Disrupting EDEM3-induced M2-like macrophage trafficking by glucose restriction overcomes resistance to PD-1/PD-L1 blockade

Shaoyong Peng , Minshan Wu , Qian Yan , Gaopo Xu , Yumo Xie , Guannan Tang , Jinxin Lin , Zixu Yuan , Xiaoxia Liang , Ze Yuan , Jingrong Weng , Liangliang Bai , Xiaolin Wang , Huichuan Yu , Meijin Huang , Yanxin Luo , Xiaoxia Liu

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (1) : e70161

PDF
Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (1) : e70161 DOI: 10.1002/ctm2.70161
RESEARCH ARTICLE

Disrupting EDEM3-induced M2-like macrophage trafficking by glucose restriction overcomes resistance to PD-1/PD-L1 blockade

Author information +
History +
PDF

Abstract

•Cancer-associated fibroblasts (CAFs) can enhance PD-L1 glycosylation through the glycosyltransferase EDEM3, contributing to immune evasion during tumour progression.

•EDEM3 predominantly activates the recruit M2-like macrophages via a glucose metabolism-dependent mechanism.

•Blocking glucose utilization antagonizes recruiting and polarizing M2-like macrophages synergistically with PD-1 antibody to improve anticancer immunity.

Keywords

2-DG / antitumour immunity / cancer-associated fibroblasts / fasting-mimicking diet / glycosyltransferase EDEM3 / M2-like macrophage / PD-L1 glycosylation

Cite this article

Download citation ▾
Shaoyong Peng, Minshan Wu, Qian Yan, Gaopo Xu, Yumo Xie, Guannan Tang, Jinxin Lin, Zixu Yuan, Xiaoxia Liang, Ze Yuan, Jingrong Weng, Liangliang Bai, Xiaolin Wang, Huichuan Yu, Meijin Huang, Yanxin Luo, Xiaoxia Liu. Disrupting EDEM3-induced M2-like macrophage trafficking by glucose restriction overcomes resistance to PD-1/PD-L1 blockade. Clinical and Translational Medicine, 2025, 15(1): e70161 DOI:10.1002/ctm2.70161

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Qu R, Ma Y, Zhang Z, Fu W. Increasing burden of colorectal cancer in China. Lancet Gastroenterol Hepatol. 2022;7:700.

[2]

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7-33.

[3]

Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7:627-647.

[4]

Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. New Engl J Med. 2015;372:2509-2520.

[5]

Wang F, Jin Y, Wang M, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nat Med. 2024;30:1035-1043.

[6]

Jin Z, Sinicrope FA. Mismatch repair-deficient colorectal cancer: building on checkpoint blockade. J Clin Oncol. 2022;40:2735-2750.

[7]

Tang H, Liang Y, Anders RA, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest. 2018;128:580-588.

[8]

Li CW, Lim S-Oe, Xia W, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.

[9]

Li CW, Lim S-Oe, Xia W, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 2018;33:187-201.e110.

[10]

Lee HH, Wang Y-N, Xia W, et al. Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy. Cancer Cell. 2019;36:168-178.

[11]

Peng S, Li Y, Huang M, et al. Metabolomics reveals that CAF-derived lipids promote colorectal cancer peritoneal metastasis by enhancing membrane fluidity. Int J Biol Sci. 2022;18:1912-1932.

[12]

Lavie D, Ben-Shmuel A, Erez N, Scherz-Shouval R. Cancer-associated fibroblasts in the single-cell era. Nat Cancer. 2022;3:793-807.

[13]

Li X, Tang B, Yujie O, Xu C, Yuan S. Single-cell RNA sequencing analysis reveals cancer-associated fibroblast signature for prediction of clinical outcomes and immunotherapy in gastric cancer. J Immunother. 2024.

[14]

Pei L, Liu Y, Liu L, et al. Roles of cancer-associated fibroblasts (CAFs) in anti-PD-1/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22:29.

[15]

McAndrews KM, Chen Y, Darpolor JK, et al. Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer. Cancer Discov. 2022;12:1580-1597.

[16]

Peng YL, Xiong LB, Zhou ZH, et al. Single-cell transcriptomics reveals a low CD8(+) T cell infiltrating state mediated by fibroblasts in recurrent renal cell carcinoma. J Immunother Cancer. 2022;10:e004206.

[17]

Zadka Ł, Chabowski M, Grybowski D, Piotrowska A, Dzięgiel P. Interplay of stromal tumor-infiltrating lymphocytes, normal colonic mucosa, cancer-associated fibroblasts, clinicopathological data and the immunoregulatory molecules of patients diagnosed with colorectal cancer. Cancer Immunol Immunother. 2021;70:2681-2700.

[18]

Galbo PM, Zang X Jr, Zheng D. Molecular features of cancer-associated fibroblast subtypes and their implication on cancer pathogenesis, prognosis, and immunotherapy resistance. Clin Cancer Res. 2021;27:2636-2647.

[19]

Li Z, Zhou J, Zhang J, Li S, Wang H, Du J. Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5. Int J Cancer. 2019;145:1946-1957.

[20]

Gao Y, Sun Z, Gu J, et al. Cancer-associated fibroblasts promote the upregulation of PD-L1 expression through Akt phosphorylation in colorectal cancer. Front Oncol. 2021;11:748465.

[21]

Wang YN, Lee HH, Hsu JL, Yu D, Hung MC. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. J Biomed Sci. 2020;27:77.

[22]

Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544-548.

[23]

Olivari S, Molinari M. Glycoprotein folding and the role of EDEM1, EDEM2 and EDEM3 in degradation of folding-defective glycoproteins. FEBS Lett. 2007;581:3658-3664.

[24]

Scott E, Garnham R, Cheung K, Duxfield A, Elliott DJ, Munkley J. Pro-survival factor EDEM3 confers therapy resistance in prostate cancer. Int J Mol Sci. 2022;24:23.

[25]

Reinfeld BI, Madden MZ, Wolf MM, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 2021;593:282-288.

[26]

Xiao S, Ma S, Sun B, et al. The tumor-intrinsic role of the m(6)A reader YTHDF2 in regulating immune evasion. Sci Immunol. 2024;9:eadl2171.

[27]

Wang L, Hu Yi-Y, Zhao J-L, et al. Targeted delivery of miR-99b reprograms tumor-associated macrophage phenotype leading to tumor regression. J Immunother Cancer. 2020;8:e000517.

[28]

Fan Y, Li Y, Yao X, et al. Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment. Gut. 2023;72:624-637.

[29]

Chen Y, Wang D, Li Y, et al. Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. Cancer Cell. 2024;42:1268-1285.

[30]

Liu C, Xie J, Lin Bo, et al. Pan-cancer single-cell and spatial-resolved profiling reveals the immunosuppressive role of APOE+ macrophages in immune checkpoint inhibitor therapy. Adv Sci (Weinh). 2024;11:e2401061.

[31]

Tang W, Lo CWS, Ma W, Chu ATW, Tong AHY, Chung BHY. Revealing the role of SPP1(+) macrophages in glioma prognosis and therapeutic targeting by investigating tumor-associated macrophage landscape in grade 2 and 3 gliomas. Cell Biosci. 2024;14:37.

[32]

Colegio OR, Chu N-Q, Szabo AL, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513:559-563.

[33]

Lee SH, Kim Y, Jeon Bu-N, et al. Intracellular adhesion molecule-1 improves responsiveness to immune checkpoint inhibitor by activating CD8(+) T cells. Adv Sci (Weinh). 2023;10:e2204378.

[34]

Tietscher S, Wagner J, Anzeneder T, et al. A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer. Nat Commun. 2023;14:98.

[35]

Narni-Mancinelli E, Campisi L, Bassand D, et al. Memory CD8+ T cells mediate antibacterial immunity via CCL3 activation of TNF/ROI+ phagocytes. J Exp Med. 2007;204:2075-2087.

[36]

Miyamoto T, Murakami R, Hamanishi J, et al. B7-H3 suppresses antitumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression. Cancer Immunol Res. 2022;10:56-69.

[37]

Yumimoto K, Akiyoshi S, Ueo H, et al. F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner. J Clin Invest. 2015;125:621-635.

[38]

Zhu M, Bai L, Liu X, et al. Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages. J Immunother Cancer. 2022;10(12):e005610.

[39]

Xu L, Li B, Pi C, et al. Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade. J Immunother Cancer. 2022;10(12):e005447.

[40]

Zhang R, Yang Y, Dong W, et al. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proc Natl Acad Sci U S A. 2022;119(8):e2114851119.

[41]

Feng R, Li Z, Ge G, Wang C, Jia Y, Ouyang J. Cancer-associated fibroblast-derived extracellular vesicles mediate immune escape of bladder cancer via PD-L1/PD-1 expression. Endocr Metab Immune Disord Drug Targets. 2023;23:1410-1420.

[42]

Yang K, Zhang J, Bao C. Exosomal circEIF3K from cancer-associated fibroblast promotes colorectal cancer (CRC) progression via miR-214/PD-L1 axis. BMC Cancer. 2021;21:933.

[43]

Guo S, Wang X, Zhou H, et al. PD-L1-mediated immunosuppression in hepatocellular carcinoma: relationship with macrophages infiltration and inflammatory response activity. Biomolecules. 2022;12(9):1226.

[44]

Murai H, Kodama T, Maesaka K, et al. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma. Hepatology. 2023;77:77-91.

[45]

Cha JH, Yang W-H, Xia W, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell. 2018;71:606-620.

[46]

Dai X, Bu X, Gao Y, et al. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Mol Cell. 2021;81:2317-2331.

[47]

Kaushik AK, Shojaie A, Panzitt K, et al. Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat Commun. 2016;7:11612.

[48]

Shi W, Cassmann TJ, Bhagwate AV, Hitosugi T, Ip WKE. Lactic acid induces transcriptional repression of macrophage inflammatory response via histone acetylation. Cell Rep. 2024;43:113746.

[49]

Cortellino S, Raveane A, Chiodoni C, et al. Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. Cell Rep. 2022;40:111256.

[50]

Guo D, Tong Y, Jiang X, et al. Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα. Cell Metab. 2022;34:1312-1324.

[51]

Shao B, Li CW, Lim SO, et al. Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. Am J Cancer Res. 2018;8:1837-1846.

[52]

Wu L, Jin Y, Zhao Xi, et al. Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-α. Cell Metab. 2023;35(9):1580-1596.e9.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

AI Summary AI Mindmap
PDF

87

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/